Delayed-Release Glucocorticoid Tablet for Rheumatoid Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glucocorticoid treatments for rheumatic diseases and osteoarthritis often involve inconvenient timing and compliance issues, with immediate-release formulations providing short-term relief but unclear long-term efficacy, especially in patients pre-treated with corticoids or experiencing circadian fluctuations in inflammatory cytokines like IL-6.
Innovation Solution
A delayed-release dosage form of glucocorticoids, such as prednisone, designed for once-daily administration, preferably at bedtime, to align with peak IL-6 levels, utilizing a press-coated tablet with a non-swellable coating that releases the active ingredient in the upper sections of the intestine within 2-6 hours, ensuring optimal timing for symptom relief and disease control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If immediate-release glucocorticoid formulations are used, then short-term symptom relief is achieved, but long-term efficacy is unclear and compliance is poor
Solution Approach 1:
The patent employs delayed-release technology to create a periodic action pattern where the glucocorticoid is released after a specific time delay (typically 4-12 hours) following administration. This allows the drug to be taken at bedtime but released during the early morning hours when inflammatory cytokines like IL-6 peak, providing sustained symptom relief while maintaining once-daily dosing for good compliance
Solution Approach 2:
The delayed-release formulation performs preliminary action by being administered before the peak inflammatory period occurs. The drug is taken at bedtime but is designed to release and become active during the early morning hours when IL-6 levels naturally peak, thereby preemptively addressing the inflammatory surge before it causes severe symptoms
2Reliability
If high doses of glucocorticoids are administered, then disease control is improved, but side effects increase
Solution Approach 1:
The patent changes the temporal parameter of drug release by using delayed-release technology. This allows optimization of the drug's pharmacokinetic profile to match the circadian rhythm of inflammatory markers, achieving better disease control at lower doses by concentrating the therapeutic effect when it is most needed (early morning) rather than maintaining constant high levels throughout the day
3Reliability
If glucocorticoids are administered to align with peak IL-6 levels, then efficacy in reducing morning stiffness is improved, but dosing timing becomes more complex
Solution Approach 1:
The delayed-release formulation performs self-service by automatically timing its release to coincide with peak IL-6 levels. The patient simply takes the medication at a convenient time (bedtime), and the formulation's built-in delay mechanism handles the timing alignment with circadian inflammatory peaks, eliminating the need for patients to calculate or adjust dosing times
Data Source
AI summary
The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.